BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
Bergen, Norway, 13 December 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it is presenting updated data from the Company’s Phase II study of bemcentinib (BCBC003) in a poster presentation today at the 63rd Annual American Society of Hematology (ASH) Meeting. Professor Sonja Loges will provide an update from the Company's Phase II study (BGBC003) of bemcentinib in combination with low dose cytarabine (LDAC) in older,